Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Legislative Reforms: Where Do We Go From Here?

Executive Summary

Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.

You may also be interested in...



340B Hospitals Could See Audits On Use Of Drug Price Savings Under Biden Administration Proposal

Legislation would be needed and will be complicated to develop. While the effectiveness of existing audits has been question by a federal government watchdog, the proposal in Biden’s budget document suggests the administration has some sympathy with drug sponsors’ position in the ongoing fight over the 340B drug discount program.

Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing

In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.

340B Reform: US House Bills Mark The End Of The Beginning

Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel